Stock Report

All about this stock under one free report Last Updated: 11-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Travere Therapeutics (TVTX) Key Ratios

Stock Card factsheet share-fund-plan-icon

$67.26

up-down-arrow $1.04 (1.56%)

As on 10-Sep-2026 14:39EDT

Market cap

info icon

$6,153 Mln

Revenue (TTM)

info icon

$591 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

258.4

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 33.32 48.17 77.12 50.60 23.70
EBIT -- -- 84.33 24.43 13.53
Net Profit 6.21 -172.81 74.29 22.95 13.33
EPS 7.83 -159.58 75.72 23.64 13.55
Book Value -- -- 78.90 23.98 -20.95
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -130.56-166.74-4.18-7.85-132.66
Net Margin info ---194.76-7.35----
Return on equity info -122.76-119.98-62.38-29.38-247.45
Return on Capital info -29.02-35.66---5.65-60.31
Return on Assets info -22.00-26.09-5.12-4.26-46.50
Debt to Equity (x) info ----24.582.866.80

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
--
-5.65
-60.31
-21.10
-54.90
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-62.38

Lower than Peers by 22.05

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
-62.38
-29.38
-247.45
-91.44
-161.46
Peer Median
-40.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-5.12

Higher than Peers by 26.12

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
-5.12
-4.26
-46.50
-15.24
-38.43
Peer Median
-31.24
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-4.18

Higher than Peers by 78.41

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
-4.18
-7.85
-132.66
-251.16
-292.47
Peer Median
-82.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-7.35

Higher than Peers by 83.95

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
-7.35
-5.21
-137.90
-76.70
-255.18
Peer Median
-91.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
--
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

77.12

Higher than Peers by 23.08

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
77.12
1.10
0.61
0.33
-0.17
Peer Median
54.03
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

84.33

Higher than Peers by 85.35

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
84.33
87.55
15.20
-13.94
-62.34
Peer Median
-1.02
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

74.29

Higher than Peers by 81.82

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
74.29
92.06
-188.64
60.00
-54.63
Peer Median
-7.53
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

75.72

Higher than Peers by 61.49

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
75.72
0.93
-1.66
0.66
-0.48
Peer Median
14.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-28.75

Lower than Peers by 18.62

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
-28.75
--
--
--
--
Peer Median
-10.13
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

24.58

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
24.58
2.86
6.80
2.02
9.51
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.25

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
0.25
0.05
1.25
0.02
0.10
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

4.05

Lower than Peers by 1.76

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
4.05
2.74
2.08
3.47
3.42
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

3.99

Lower than Peers by 1.70

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
3.99
2.70
2.04
3.41
3.39
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-6.07

Lower than Peers by 3.99

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
-6.07
-3.58
-27.66
-32.18
-29.07
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

13.64

Lower than Peers by 5.38

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
13.64
16.33
11.63
14.58
15.21
Peer Median
19.01
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.70

Higher than Peers by 0.63

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
0.70
0.82
0.34
0.20
0.15
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
--
39.91
37.83
47.56
54.32
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
--
213.29
368.13
222.23
489.04
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
--
853.76
1,537.81
940.48
1,340.10
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
--
-600.55
-1,131.86
-670.69
-796.74
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
--
-135.06
-4.50
-6.17
-4.85
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

258.35

Higher than Peers by 253.02

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
258.35
30.05
24.51
3.42
31.51
Peer Median
5.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

1,118.75

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
1,118.75
155.55
-5.56
-1.61
-4.37
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

6,153

Higher than Peers by 6,012

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Travere Therapeutics (TVTX)
6,153
--
--
--
--
Peer Median
142
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...